FluoGuide (OM:FLUO) - Hisse Senedi Fiyatı, Haberler ve Analizler

FLUO Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan FluoGuide A/S, Danimarka'da kanseri floresan hale getirerek cerrahi sonuçlar için ilaç geliştirmeye odaklanmıştır. Daha fazla detay

FLUO temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 85% daha düşük bir oranda işlem görüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( DKK1M )

1 yıldan az nakit akışı var

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir piyasa değeri yok ( SEK488M )

+ 1 daha fazla risk

FluoGuide A/S Rakipler

Hamlet BioPharma

NGM:HAMLET B

SEK 473.1m

Oncopeptides

OM:ONCO

SEK 309.4m

Isofol Medical

OM:ISOFOL

SEK 529.0m

Medivir

OM:MVIR

SEK 302.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti FluoGuide
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 35.85
52 Haftanın En Yüksek Seviyesi	SEK 80.00
52 Haftanın En Düşük Seviyesi	SEK 32.00
Beta	1.13
11 Aylık Değişim	-6.52%
3 Aylık Değişim	-11.04%
1 Yıllık Değişim	-51.42%
33 Yıllık Değişim	-60.73%
5 Yıllık Değişim	540.18%
Halka arzdan bu yana değişim	547.11%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	FLUO	SE Biotechs	SE Pazar
7D	5.3%	-3.8%	-1.9%
1Y	-51.4%	17.8%	12.5%

Getiri vs. Endüstri: FLUO geçen yıl % 17.8 oranında getiri sağlayan Swedish Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: FLUO geçen yıl % 12.5 oranında getiri sağlayan Swedish Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is FLUO's price volatile compared to industry and market?
FLUO volatility
FLUO Average Weekly Movement	5.5%
Biotechs Industry Average Movement	9.1%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

İstikrarlı Hisse Senedi Fiyatı: FLUO son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: FLUO 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2018	8	Morten Albrechtsen	fluoguide.com

Klinik aşamada bir biyoteknoloji şirketi olan FluoGuide A/S, Danimarka'da kanseri floresan hale getirerek cerrahi sonuçlar için ilaç geliştirmeye odaklanmıştır. Şirketin öncü ürün adayı olan FG001, yüksek dereceli glioma tedavisi için Faz IIa ve IIb; akciğer kanseri ve baş ve boyun kanseri tedavisi için Faz II klinik çalışmalarında yer almaktadır. Şirket ayrıca, yeni bir uPAR-hedefli lüminesan teknolojisi aracılığıyla cerrahların ameliyat sırasında kanseri normal dokudan ayırt etmelerini sağlayan klinik öncesi aşamada olan FG002'yi geliştirmektedir.

FluoGuide A/S Temel Bilgiler Özeti

FluoGuide'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
FLUO temel i̇stati̇sti̇kler
Piyasa değeri	SEK 487.91m
Kazançlar(TTM)	-SEK 56.51m
Gelir(TTM)	SEK 1.90m

257.0x

P/S Oranı

-8.6x

F/K Oranı

FLUO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
FLUO gelir tablosu (TTM)
Gelir	DKK 1.22m
Gelir Maliyeti	DKK 0
Brüt Kâr	DKK 1.22m
Diğer Giderler	DKK 37.65m
Kazançlar	-DKK 36.43m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 28, 2024

Hisse başına kazanç (EPS)	-2.68
Brüt Marj	100.00%
Net Kâr Marjı	-2,976.06%
Borç/Özkaynak Oranı	0%

FLUO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

FLUO Stoklara Genel Bakış

Ödüller

Risk Analizi

FluoGuide A/S Rakipler

NGM:HAMLET B

SEK 473.1m

OM:ONCO

SEK 309.4m

OM:ISOFOL

SEK 529.0m

OM:MVIR

SEK 302.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

FluoGuide A/S Submits Clinical Trial Application for Phase II Trial in Head and Neck Cancer

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Recent updates

Fluoguide A/S Announces Roger Gunnarsson Resigns as Board Member

FluoGuide A/S Submits Clinical Trial Application for Phase II Trial in Head and Neck Cancer

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma